Is HARP or JEPQ a better dividend investment in 2026?

HARP currently yields 8.69% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: JEPQ offers higher current income.

What is the dividend yield difference between HARP and JEPQ?

HARP has a forward dividend yield of 8.69% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 2.41 percentage points.

Home › Compare › HARP vs JEPQ

HARP vs JEPQ: Dividend Comparison 2026

HARP yields 8.69% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JEPQ wins by $9.2K in total portfolio value

INVESTMENT

TIME HORIZON10 years

HARP

● Live price

8.69%

Share price

$23.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$35.6K

Annual income

$1,504.59

Full HARP calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — HARP vs JEPQ

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	HARP	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, HARP + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

HARP pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HARP

Annual income on $10K today (after 15% tax)

$738.81/yr

After 10yr DRIP, annual income (after tax)

$1,278.90/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, JEPQ beats the other by $550.80/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HARP + JEPQ for your $10,000?

HARP: 50%JEPQ: 50%

100% JEPQ50/50100% HARP

Portfolio after 10yr

$40.2K

Annual income

$1,828.58/yr

Blended yield

4.55%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on HARP right now

HARP

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$700.00

+2942.2% upside vs current

Range: $700.00 — $700.00

Altman Z

0.4

Piotroski

2/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HARP buys

JEPQ buys

No recent congressional trades found for HARP or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricHARPJEPQ

Forward yield	8.69%	11.10% ✓
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$35.6K	$44.8K ✓
Annual income after 10y	$1,504.59	$2,152.59 ✓
Total dividends collected	$11.9K	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: HARP vs JEPQ ($10,000, DRIP)

Year	HARP Portfolio	HARP Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$11,569	$869.19	$11,930	$1,110.39	$361.00 → JEPQ
2	$13,319	$939.79	$14,133	$1,224.34	$814.00 → JEPQ
3	$15,262	$1,011.14	$16,632	$1,340.46	$1.4K → JEPQ
4	$17,414	$1,082.88	$19,454	$1,457.97	$2.0K → JEPQ
5	$19,787	$1,154.69	$22,626	$1,576.08	$2.8K → JEPQ
6	$22,399	$1,226.25	$26,175	$1,694.09	$3.8K → JEPQ
7	$25,264	$1,297.27	$30,133	$1,811.32	$4.9K → JEPQ
8	$28,400	$1,367.49	$34,531	$1,927.17	$6.1K → JEPQ
9	$31,824	$1,436.67	$39,403	$2,041.08	$7.6K → JEPQ
10	$35,557	$1,504.59	$44,787	$2,152.59	$9.2K → JEPQ

HARP vs JEPQ: Complete Analysis 2026

HARP — Stock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Full HARP Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this HARP vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HARP vs SCHD HARP vs JEPI HARP vs O HARP vs KO HARP vs MAIN HARP vs XYLD HARP vs QYLD HARP vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.